<DOC>
	<DOC>NCT01368081</DOC>
	<brief_summary>The objective of the study is to investigate the long-term safety and efficacy of BI 10773 given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2 diabetes mellitus with insufficient glycaemic control.</brief_summary>
	<brief_title>Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria: .Diagnosis of type 2 diabetes mellitus prior to informed consent Male and female patients, on diet and exercise regimen, who are pretreated with one of the following oral antidiabetic drugs: sulfonylurea, glinide, biguanide, Alphaglucosidase inhibitor (aGI), dipeptidyl peptidaseIV (DPPIV) inhibitor or thiazolidinedione glycosylated haemoglobin (HbA1c) at Visit 1: &gt;=7.0 to =&lt;10.0% (national glycohemoglobin standardization program) Exclusion criteria: Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dL (&gt;13.3 mmol/L) Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>